Baker Bros. Advisors LP Madrigal Pharmaceuticals, Inc. Transaction History
Baker Bros. Advisors LP
- $9.34 Billion
- Q3 2024
A detailed history of Baker Bros. Advisors LP transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Baker Bros. Advisors LP holds 1,974,590 shares of MDGL stock, worth $686 Million. This represents 4.49% of its overall portfolio holdings.
Number of Shares
1,974,590
Previous 1,974,590
-0.0%
Holding current value
$686 Million
Previous $553 Million
24.25%
% of portfolio
4.49%
Previous 7.35%
Shares
8 transactions
Others Institutions Holding MDGL
# of Institutions
296Shares Held
22MCall Options Held
819KPut Options Held
640K-
Janus Henderson Group PLC London, X02.48MShares$861 Million0.28% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny2.04MShares$709 Million29.57% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.03MShares$705 Million6.48% of portfolio
-
Rtw Investments, LP New York, NY1.99MShares$693 Million6.74% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.83MShares$637 Million0.01% of portfolio
About MADRIGAL PHARMACEUTICALS, INC.
- Ticker MDGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,103,400
- Market Cap $5.94B
- Description
- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...